Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.04 Analyst target: $17.11 Upside: 738.73%
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.